GlassScriptPhysician profile
Kimberly Ann Pierce
NPI 1891761441
$7,429.81
in general payments reported to CMS, 2019-2025
41 companies · $2,295 in 2025
The $2,295 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $998 · 2022: $1,315 · 2023: $1,400 · 2024: $1,423 · 2025: $2,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,255 · Travel and Lodging: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.13 |
| Travel and Lodging | $861.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,034.05 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $866.48 | 2021-2025 | |
| Medical Device Business Services, INC. | $618.52 | 2025 | Carto 3 |
| Pfizer INC. | $602.02 | 2021-2025 | |
| Biosense Webster, INC. | $439.50 | 2025 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $424.37 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.68 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $344.96 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $298.88 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Merck Sharp & Dohme LLC | $244.10 | 2023-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $201.38 | 2024 | Arcalyst |
| Boston Scientific Corporation | $178.14 | 2023-2025 | Farapulse, Watchman Flx, Watchman Access System |
| Scpharmaceuticals INC. | $174.89 | 2023-2025 | |
| Daiichi Sankyo INC. | $157.61 | 2022-2023 | Injectafer |
| Edwards Lifesciences Corporation | $154.00 | 2021-2025 | Sapien 3 Ultra Resilia |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $136.33 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bridgebio Pharma, INC. | $106.10 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $99.08 | 2021-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $95.08 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $78.25 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.30 | 2021-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $65.01 | 2022-2023 | |
| Baxter Healthcare | $64.80 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $54.06 | 2024-2025 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $49.20 | 2024-2025 | Uptravi, Opsumit |
| Abiomed | $45.35 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $41.73 | 2024-2025 | Evkeeza, Dupixent |
| Cardiva Medical, INC. | $41.31 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Abbott Laboratories | $39.49 | 2021-2024 | Gallant |
| Philips North America LLC | $38.12 | 2024 | (Ao0) Igt Devices Intracardiac |
| Bayer Healthcare Pharmaceuticals INC. | $37.94 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $37.62 | 2021-2022 | |
| Amarin Pharma, INC. | $35.81 | 2021-2022 | |
| Genzyme Corporation | $24.26 | 2022 | |
| Inspire Medical Systems, INC. | $24.04 | 2024 | Inspire |
| Becton, Dickinson and Company | $23.55 | 2024 | |
| Astellas Pharma US INC | $19.55 | 2021 | |
| Corcept Therapeutics | $16.26 | 2025 | Korlym |
| Kestra Medical Technology Services, INC. | $15.84 | 2024 | Assure Wcd |
| Amryt Pharma Holdings LTD | $15.76 | 2021 | |
| Atricure, INC. | $14.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.